# Constance Cirrincione

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/constance-cirrincione/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,649 |
| Field | Breast Cancer Treatment Studies |
| h-index | 45 |
| i10-index | 71 |
| OpenAlex ID | https://openalex.org/A5001268619 |
| Works | 118 |

## Researcher papers

- [Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://scholariq.org/papers/randomized-trial-of-dose-dense-versus-conventionally-scheduled-and-sequential/)
- [Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343](https://scholariq.org/papers/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or/)
- [Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer](https://scholariq.org/papers/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-70-years-of-age/)
- [Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)](https://scholariq.org/papers/impact-of-the-addition-of-carboplatin-and-or-bevacizumab-to-neoadjuvant-once-per/)
- [Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/)
- [Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials](https://scholariq.org/papers/increasing-the-dose-intensity-of-chemotherapy-by-more-frequent-administration-or/)
- [Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials](https://scholariq.org/papers/anthracycline-containing-and-taxane-containing-chemotherapy-for-early-stage/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.